Phio Pharmaceuticals (PHIO) Stock Price, News & Analysis

Company Overview

Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.

Key Stats

• Today's Range: $1.57 to $1.81
• 50-Day Range: $1.74 to $3.29
• 52-Week Range: $1.53 to $10.35
• Volume: 345,059 shs
• Average Volume: 69,121 shs
• Market Capitalization: $1.86 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $36.00
• Consensus Rating: Buy

Phio Pharmaceuticals Stock Analysis - MarketRank™

Phio Pharmaceuticals scored higher than 32% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Phio Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Phio Pharmaceuticals has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Phio Pharmaceuticals is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Phio Pharmaceuticals is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Phio Pharmaceuticals has a P/B Ratio of 0.09. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.72% of the float of Phio Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Phio Pharmaceuticals has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Phio Pharmaceuticals has recently increased by 0.21%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Phio Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Phio Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.72% of the float of Phio Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Phio Pharmaceuticals has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Phio Pharmaceuticals has recently increased by 0.21%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 1 people have searched for PHIO on MarketBeat in the last 30 days. This is a decrease of -94% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Phio Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.59% of the stock of Phio Pharmaceuticals is held by insiders.

Percentage Held by Institutions

57.31% of the stock of Phio Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PHIO Stock Analysis - Frequently Asked Questions

How have PHIO shares performed this year?

Phio Pharmaceuticals' stock was trading at $6.84 on January 1st, 2024. Since then, PHIO shares have decreased by 74.3% and is now trading at $1.76.
View the best growth stocks for 2024 here.

How were Phio Pharmaceuticals' earnings last quarter?

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) issued its earnings results on Wednesday, August, 14th. The company reported ($3.62) earnings per share for the quarter, topping analysts' consensus estimates of ($4.59) by $0.97.

When did Phio Pharmaceuticals' stock split?

Phio Pharmaceuticals's stock reverse split before market open on Friday, July 5th 2024. The 1-9 reverse split was announced on Friday, July 5th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 11 shares after the split.

How do I buy shares of Phio Pharmaceuticals?

Shares of PHIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Phio Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Phio Pharmaceuticals investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), NIO (NIO), AST SpaceMobile (ASTS), Phunware (PHUN) and Virgin Galactic (SPCE).

Company Calendar

• Last Earnings: 8/14/2024
• Today: 12/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PHIO
• CUSIP: N/A
• CIK: 1533040
• Web: phiopharma.com
• Phone: (508) 767-3861
• Fax: 508-767-3862
• Employees: 8
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $36.00
• High Stock Price Target: $36.00
• Low Stock Price Target: $36.00
• Potential Upside/Downside: +1,945.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($10.92)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-10,830,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -134.57%
• Return on Assets: -108.39%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.38
• Quick Ratio: 6.38

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $18.57 per share
• Price / Book: 0.09

Miscellaneous

• Outstanding Shares: 1,055,000
• Free Float: 1,049,000
• Market Cap: $1.86 million
• Optionable: Not Optionable
• Beta: 1.49